A
Ah Ting Tam
Researcher at Harvard University
Publications - 3
Citations - 2427
Ah Ting Tam is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Biomarker discovery. The author has an hindex of 3, co-authored 3 publications receiving 2136 citations.
Papers
More filters
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Anthony C. Faber,Erin M. Coffee,Carlotta Costa,Anahita Dastur,Hiromichi Ebi,Aaron N. Hata,Alan T. Yeo,Elena J. Edelman,Youngchul Song,Ah Ting Tam,Jessica L. Boisvert,Randy J. Milano,Jatin Roper,David P. Kodack,Rakesh K. Jain,Ryan B. Corcoran,Miguel Rivera,Sridhar Ramaswamy,Kenneth E. Hung,Cyril H. Benes,Jeffrey A. Engelman +20 more
TL;DR: The data suggest that the combination of BCL-2/BCL-XL inhibitors with TORC1/2 inhibitors constitutes a promising targeted therapy strategy to treat these recalcitrant cancers.
Journal ArticleDOI
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
Anthony C. Faber,Anna F. Farago,Anna F. Farago,Carlotta Costa,Anahita Dastur,Maria Gomez-Caraballo,Rebecca Robbins,Bethany L. Wagner,William M. Rideout,Charles T. Jakubik,Jungoh Ham,Elena J. Edelman,Hiromichi Ebi,Alan T. Yeo,Aaron N. Hata,Youngchul Song,Neha U. Patel,Ryan J. March,Ah Ting Tam,Randy J. Milano,Jessica L. Boisvert,Mark A. Hicks,Sarah Elmiligy,Scott E. Malstrom,Miguel Rivera,Hisashi Harada,Brad Windle,Sridhar Ramaswamy,Cyril H. Benes,Tyler Jacks,Jeffrey A. Engelman +30 more
TL;DR: The sensitivity of a large panel of cancer cell lines, including SCLC, to ABT-263 is examined and it is found that high Bcl2-interacting mediator of cell death (BIM) and low myeloid cell leukemia 1 (MCL-1) expression together predict sensitivity.